Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;13(1):105-108.
doi: 10.21037/hbsn-23-582. Epub 2024 Jan 10.

CAIRO5 study from a surgical perspective

Andrius Meskauskas  1 , Maximiliano Gelli  1   2
Affiliations
Editorial

CAIRO5 study from a surgical perspective

Andrius Meskauskas et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Metastatic colorectal cancer (metastatic CRC); immunotherapy; liver metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-582/coif). The authors have no conflicts of interest to declare.

Comment on

  • Lancet Oncol. 24:757.

References

    1. Bond MJG, Bolhuis K, Loosveld OJL, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol 2023;24:757-71. 10.1016/S1470-2045(23)00219-X - DOI - PubMed
    1. Watanabe J, Muro K, Shitara K, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2023;329:1271-82. 10.1001/jama.2023.4428 - DOI - PMC - PubMed
    1. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015;26:702-8. 10.1093/annonc/mdu580 - DOI - PubMed
    1. Ychou M, Rivoire M, Thezenas S, et al. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. Br J Cancer 2022;126:1264-70. 10.1038/s41416-021-01644-y - DOI - PMC - PubMed
    1. Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol 2019;37:3401-11. 10.1200/JCO.19.01340 - DOI - PubMed

Publication types

LinkOut - more resources